Hu, Limin <br/><br/>
Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.  [electronic resource] 

 -  The American journal of pathology  Nov 2002 
 - 1917-24 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0002-9440 
<br/><br/><label>Standard No.: </label>10.1016/S0002-9440(10)64467-7  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--therapeutic use<br/>Antineoplastic Agents, Phytogenic--therapeutic use<br/>Apoptosis<br/>Ascites--prevention & control<br/>Carcinoma--drug therapy<br/>Cell Division<br/>Combined Modality Therapy<br/>Endothelial Growth Factors--antagonists & inhibitors<br/>Female<br/>Intercellular Signaling Peptides and Proteins--immunology<br/>Lymphokines--antagonists & inhibitors<br/>Mice<br/>Mice, Nude<br/>Neutralization Tests<br/>Ovarian Neoplasms--drug therapy<br/>Paclitaxel--therapeutic use<br/>Tumor Cells, Cultured<br/>Vascular Endothelial Growth Factor A<br/>Vascular Endothelial Growth Factors